RNA-based therapeutics exhibit significant potential in treating various diseases, including Covid-19. These therapeutics function by either suppressing pathological genes through siRNA delivery or expressing therapeutic proteins via the introduction of exogenous mRNA into cells. Despite their promise, mRNA molecules pose challenges due to their size, fragility, and susceptibility to degradation. Crossing plasma membranes to access target cells is not facile, necessitating the development of an effective delivery solution. While lipid nanoparticle delivery platforms have undergone extensive research and optimization for formulating oligonucleotide drug products, they now offer a solid foundation for mRNA-based systems. However, it is crucial to note that LNPs containing mRNA require distinct treatment compared to those containing oligonucleotides, as the particle structure significantly influences stability under processing conditions.
